RyanChristopherLynchMD

PubMed

• Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
  Thomas M Kuczmarski, Ryan C Lynch> ;British Journal of Haematology. 2024 May 2
• Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
  Fakhri, B., Laura Samples, Jenna M Voutsinas MPH, Bita Fakhri, Sirin Khajavian, Stephen E Spurgeon, Deborah M Stephens, Alan P Skarbnik, Anthony R Mato, Catherine Broo...> ;Blood Advances. 2024 Feb 2
• 1 citations
  Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
  Steiner, R., Hwang, S., Khurana, A., Habermann, T., Epperla, N., Annunzio, K., Allen, P., Baird, K., Paulino, D., Alderuccio, J., Lossos, I., David, K., Evens, A., Pan...> ;Blood Advances. 2023 Dec 26
• 4 citations
  Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
  Jin, M., Stefan K Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Yu Li, Cédric Rossi, Tim Flerlage, Jamie E Flerlage, Ragini Adams, Michael S Binkley, Navi...> ;Nature. 2024 Jan 1
• Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
  Carrie Ho, Ajay K Gopal, Brian G Till, Mazyar Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
• 3 citations
  Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
  Marek Trněný, Abraham Avigdor, Matthew S McKinney, Shankara Paneesha, Björn E Wahlin, John S Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Or...> ;Eclinicalmedicine. 2023 Sep 1
• 1 citations
  Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
  Ryan C Lynch, Christina Poh, Chaitra S Ujjani, Edus H Warren, Stephen D Smith, Mazyar Shadman, Karolyn Morris, Sydney Lee, Heather Rasmussen, Susan Ottemiller, Megan S...> ;Blood Advances. 2023 Jun 13
• 14 citations
  Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
  Ryan C Lynch, Chaitra S Ujjani, Christina Poh, Edus H Warren, Stephen D Smith, Mazyar Shadman, Brian Till, Vikram M Raghunathan, Stefan Alig, Ash A Alizadeh, Avanti Gu...> ;Blood. 2023 May 25
• 1 citations
  Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
  Solomon A Graf, Ryan C Lynch, Chaitra S Ujjani, Ted A Gooley, Heather Rasmussen, David G Coffey, Andrew J Cowan, Stephen D Smith, Mazyar Shadman, Edus H Warren, Edward...> ;Blood Advances. 2023 Mar 14
• 2 citations
  Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
  Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, Lorena Panaite, Erin Mullane, Ryan C Lynch, Chaitra Ujjani, Stephen D Smith, Ajay K Gopal, Brian G Till, Filippo Milano...> ;Journal of Cellular and Molecular Medicine. 2022 Dec 1
• 7 citations
  Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
  Portuguese, A. J., Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, Chih-Yuan Hsu, Yu Shyr, Shailesh Advani, Ruben A Mesa, Sanjay Mishra, Daniel P Mundt, Dimpy P Sha...> ;Blood Cancer Discovery. 2022 May 5
• 9 citations
  The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
  Chaitra Ujjani, Mazyar Shadman, Ryan C Lynch, Brian Tu, Philip A Stevenson, Caitlin Grainger, Haiying Zhu, Joshua A Hill, Meei-Li Huang, Leslie Nielsen, Christina Poh,...> ;British Journal of Haematology. 2022 May 1
• 2 citations
  Heterologous SARS-CoV-2 Vaccinations in Patients with B-cell Lymphoid Malignancies.
  Chaitra S. Ujjani, Alexander L. Greninger, Mazyar Shadman, Joshua A. Hill, Ryan C. Lynch, Edus H. Warren, Ajay K. Gopal> ;American Journal of Hematology. 2021 Nov 22
• 25 citations
  Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single cen...
  Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujj...> ;The Lancet. Haematology. 2021 Aug 1
• 21 citations
  Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
  Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio C. Chavez, Yago Nieto, Justin Darrah, Uttam Rao, Michael Byrne, David A. Bond, Kami J. Maddocks, Michael A. Sp...> ;Blood Advances. 2021 Mar 23
• 42 citations
  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
  Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A. Bond, Samantha Jaglowski, Michael A. Spinner...> ;Leukemia. 2021 Mar 3
• 18 citations
  Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
  Stephen D. Smith, Paolo Lopedote, Yazeed Samara, Matthew Mei, Alex F. Herrera, Allison M. Winter, Brian T. Hill, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Caro...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 1
• 22 citations
  A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Cancer Cell. 2020 Dec 14
• 9 citations
  Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
  Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, Jenna M. Voutsinas, Qian Vicky Wu, Sanaz Behnia, Ryan C. Lynch, Elizabeth F. Krakow, Heather Rasmussen, Thomas R. Ch...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 1
• 85 citations
  Hodgkin lymphoma, version 2.2020
  Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M Boughan, Bout...> ;Journal of the National Comprehensive Cancer Network. 2020 Jun 1
• 18 citations
  Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
  Mary Elizabeth Percival, Ryan C. Lynch, Anna B. Halpern, Mazyar Shadman, Ryan D. Cassaday, Chaitra S. Ujjani, Andrei R. Shustov, Yolanda D. Tseng, Catherine Liu, Steve...> ;JCO Oncology Practice. 2020 May 5
• 1 citations
  Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Insti...
  Ryan C. Lynch, Vandana Sundaram, Manisha Desai, Solomon Henry, Douglas J. Wood, Sarah E. Daadi, Richard T. Hoppe, Ranjana H. Advani> ;JCO Oncology Practice. 2020 May 5
• 1 citations
  Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma.
  Ryan C. Lynch, Ajay K. Gopal> ;Hematology/oncology Clinics of North America. 2020 Apr 9
• 59 citations
  Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
  Stephen D. Smith, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian Wu, Jenna M. Voutsinas, Heather Rasmussen, Katherine Blue, Chaitra S. Ujjani, And...> ;British Journal of Haematology. 2020 Feb 6
• 5 citations
  Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
  A. Kim, Philip A. Stevenson, Ryan D. Cassaday, Lori Soma, Jonathan R. Fromm, Ajay K. Gopal, Stephen D. Smith, Brian G. Till, Ryan C. Lynch, Chaitra S. Ujjani, Mazyar S...> ;Practical Radiation Oncology. 2020 Jan 1
• Join now to see all

Abstracts/Posters

• Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
  Ryan C. Lynch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019